I attended a lunchtime Roundtable event yesterday organised by the European Policy Centre here in Brussels. The speaker was Dr Martin Terberger, Head of Unit for Pharmaceuticals at DG Enterprise and Industry. While the focus of the discussion was the so-called ‘Pharma Package’ a set of EU proposals to deliver safe, innovative and accessible medicines, I was able to ask Dr Terberger a question about the impact which differences in Health Technology Assessment (HTA) helped or hindered accessibility, especially if one outcome was to support the labour market participation of people with long-term or chronic conditions (eg some MSDs).
He was careful to avoid using the term ‘harmonisation’ but felt that, on the science, there was more room for ‘convergence’ around the clinical evidence. He warned, however, that HTA must take care not to widen health inequalities by treating more economically ‘useful’ patients differently from, for example, elderly patients just because of differences in their productive capacity.
This entry was posted on Wednesday, November 18th, 2009 at 9:29 am and is filed under Europe, Health Policy, Musculoskeletal Disorders, Organisations, Policy, The Work Foundation. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.